CDK4 and breast neoplasm: In the multidisciplinary management of patients with HR+/HER2− advanced breast tumors with bone metastases, the integration of radiotherapy (RT) with CDK4/6 inhibitors remains a clinical challenge, with several aspects yet to be fully clarified.